 | |
 | |
| Clinical data | |
|---|---|
| Other names | 5-Methoxy-N,N-diethyltryptamine |
| Routes of administration | Oral,smoking[1] |
| Drug class | Serotonin receptor agonist;Serotonin5-HT2A receptoragonist;Serotonergic psychedelic;Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | Oral: 20–30 minutes[1] Smoking: A few minutes[1] |
| Duration of action | Oral: 3–4 hours[1] Smoking: 1.5 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
5-MeO-DET, also known as5-methoxy-N,N-diethyltryptamine is apsychedelic drug of thetryptamine family related to5-MeO-DMT.[1] It is takenorally but can also be usedparenterally.[1]
The drug produces strongside effects such aslightheadedness,dizziness, andvertigo at low doses that preventhallucinogenic doses from beingtolerated or used.[1] It acts as aserotonin receptor modulator, including as anagonist of theserotonin5-HT2A receptor.[2][3][4][5][6][7] 5-MeO-DET produces psychedelic-like effects in animals.[8][9][7]Analogues of 5-MeO-DET include 5-MeO-DMT,5-MeO-DPT,dipropyltryptamine (DPT), and4-HO-DPT (deprocin), among others.[1]
5-MeO-DET was first described in the literature by 1968.[10] It was further described byAlexander Shulgin in his 1997 bookTiHKAL (Tryptamines I Have Known and Loved).[1] The drug was encountered as a noveldesigner drug in 2005.[11]
In his bookTiHKAL (Tryptamines I Have Known and Loved),Alexander Shulgin lists 5-MeO-DET's dose as 1 to 3 mgorally and itsduration as 3 to 4 hours.[1] Theonset was reported to be 20 to 30 minutes.[1] There was also a report ofsmoking at a dose of 10 mg, with an onset of a few minutes and a duration of 1.5 hours, but this dose resulted in strongside effects that resulted in the user describing it as a "torture psychedelic".[1]
The effects of 5-MeO-DET at oral doses have been reported to include stronglightheadedness,dizziness,vertigo, spaciness, body heaviness, fragility, need to lay down and stay that way,intoxication,drunkenness,uncomfortableness,negative mood,depression,tinnitus,sexual enhancement, wanting the drug to wear off as soon as possible, and unwillingness to take the drug again.[1] Although there was an awareness of another interesting dimension beyond the side effects, there was a sense of the lightheadedness blocking everything else.[1] This side effect was described as not being due tohypotension or dizziness but perhaps being something to do with theinner ear (e.g., vertigo).[1] According to one report, if the lightheadedness or dizziness could be removed, 5-MeO-DET would be one of the best drugs foreroticism imaginable.[1] In the high-dose smoked report, the effects included dizziness,intense heartbeat,trembling,anxiety,restlessness,cold sweating,paleness,abdominal cramps,feeling sick, some "visions", inability to concentrate on the visionary effects due to side effects, and feeling very glad when the drug wore off.[1] As mentioned previously, the user described 5-MeO-DET as a "torture psychedelic" with this route and dose.[1]
According to Shulgin, 5-MeO-DET possesses an unexpected new property of lightheadedness, vertigo, and intoxication suggestive of "neurotoxicity" that emerges at very low doses and that has not been observed with other5-methoxytryptamines.[1] These side effects have effectively precluded exploration of and ability to tolerate higher doses of the drug.[1] Per Shulgin, based on extrapolation from its lower and higherhomologues5-MeO-DMT and5-MeO-DiPT, respectively, 5-MeO-DET is anticipated to be an active psychedelic at doses of 10 mg or moreparenterally and probably orally, but these doses cannot be achieved due to its strong side effects.[1] This resulted in Shulgin stating that 5-MeO-DET was "one of the most provocative temptresses I have ever encountered" among the tryptamines and that it was a case of "having a protégé that you absolutely know will be a success if allowed to come to fulfillment, and yet you know that uncontrolled circumstances will prevent that fulfillment".[1] He has said that these side effects may be unique to 5-MeO-DET and also pondered whether the same action that causes them could simultaneously be responsible for the "terrific erotic enhancement" the drug produces.[1]
5-MeO-DET's higher homologue5-MeO-DPT was also tested by Shulgin in hopes that the vertigo-related side effects could be removed.[1] His experience with this drug was mixed, with it being better-tolerated and allowing for higher doses than 5-MeO-DET, but side effects nonetheless still outweighing desired effects.[1] Shulgin explored and hypothesized about other possible 5-methoxytryptamines as well.[1]
5-MeO-DETinhibits serotonin reuptake with anIC50Tooltip half-maximal inhibitory concentration value of 2,400 nM and activates theserotonin5-HT2A receptor with anEC50Tooltip half-maximal effective concentration value of 8.1 nM.[2][3][4][5][6][10][12] The drug fully substitutes forDOM in rodentdrug discrimination tests.[8] It also substitutes for5-MeO-DMT in rodent drug discrimination tests.[9] In addition, 5-MeO-DET produces thehead-twitch response in rodents.[7]
Thechemical synthesis of 5-MeO-DET has been described.[1]
Analogues of 5-MeO-DET includediethyltryptamine (DET),4-HO-DET (ethocin),ethocybin (4-PO-DET),5-HO-DET,5-MeO-DMT,5-MeO-DPT,5-MeO-DiPT,5-MeO-DALT,5-MeO-MET,5-MeO-MPT,5-MeO-MiPT,5-MeO-pyr-T, and4-MeO-DET, among others.[1]
5-MeO-DET was first described in thescientific literature by 1968.[10] It was described in greater detail byAlexander Shulgin in his 1997 bookTiHKAL (Tryptamines I Have Known and Loved).[1] The drug was encountered as a noveldesigner drug inEurope in 2005.[11]
